A randomized study to evaluate safety and efficacy of transitioning therapy from alendronate [alendronic acid] to denosumab (AMG 162) in postmenopausal women with low bone mineral density
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms STAND
- Sponsors Amgen
- 20 Oct 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 18 Oct 2009 Results presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals.
- 11 Jun 2009 Results published as an abstract in the proceedings of the 91st Annual Meeting of the Endocrine Society (ENDO 2009).